Research programme: macrocyclic peptide therapeutics - PeptiDream/Shionogi

Drug Profile

Research programme: macrocyclic peptide therapeutics - PeptiDream/Shionogi

Latest Information Update: 24 Jun 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator PeptiDream; Shionogi
  • Class Macrocyclic compounds; Peptides
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Research Unspecified

Most Recent Events

  • 12 Jun 2017 PeptiDream non-exclusively licenses its Peptide Discovery Platform System (PDPS) to Shionogi for use in development of macrocyclic peptides
  • 05 Feb 2016 Early research in Undefined indication in Japan (unspecified route)
  • 05 Feb 2016 Shionogi and PeptiDream agree to co-develop and co-promote macrocyclic/ constrained peptides in Japan
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top